新綸新材(002341.SZ):增持期過半 董事長及其控制的企業、管理層人員累計增持20萬股
格隆匯1月13日丨新綸新材(002341.SZ)公佈,截至2022年1月13日,此次增持計劃期間過半,公司董事長兼總裁廖垚及其控制的企業深圳市上元資本管理有限公司,及董事兼常務副總裁李靖彬、董事兼副總裁兼董事會祕書李洪流、董事兼副總裁市東一元、副總裁李洪亮、副總裁楊棟、財務總監陳得勝、審計總監崔金山、總裁助力徐世穎(簡稱“管理層人員”)通過深圳證券交易所交易系統以集中競價方式累計增持公司股份20萬股,佔公司總股本的0.017%,增持金額為人民幣105.60萬元。本次增持計劃尚未實施完畢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.